Back to Results

A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus

Study category: Bones, Muscles, and Joints

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

Barbara Davis Center

Principal Investigator
Christopher Striebich,  MD, PhD

Christopher Striebich, MD, PhD

Study ID

Protocol Number: 19-0027

More information available at ClinicalTrials.gov: NCT03724916

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers